IDEAS home Printed from https://ideas.repec.org/a/plo/pone00/0220605.html
   My bibliography  Save this article

Gap analysis for drug development policy-making: An attempt to close the gap between policy and its implementation

Author

Listed:
  • Ria Christine Siagian
  • Dumilah Ayuningtyas

Abstract

Introduction: Most drug development policies in developing countries are enacted without achieving the desired results. This study aims to determine the prioritization of drug development in Indonesia through the evidence-based policymaking process in order to close the distance between stated policy goals and the realization of planned goals. Methods: A quantitative approach in the form of cross-sectional research using a structured survey was adopted and validated using a set of techniques involved in the calculation of a structural equation model. An independent samples t-test was used to test the significance of the differences between two views: pharmaceutical industries and the government of Indonesia. Findings: The study reveals that pharmaceutical industries and governments were highly consistent in their perceived challenges in facing the drug development. It also reveals drivers and weaknesses of drug development, including market opportunities, push-pull-regulatory pull factors and regulation, as priorities for improvement. Conclusions: Gap analysis based on a structural model was borne out to address gap challenges between policy and its implementation, with the use of evidence-based policymaking.

Suggested Citation

  • Ria Christine Siagian & Dumilah Ayuningtyas, 2019. "Gap analysis for drug development policy-making: An attempt to close the gap between policy and its implementation," PLOS ONE, Public Library of Science, vol. 14(8), pages 1-13, August.
    • Handle: RePEc:plo:pone00:0220605
    DOI: 10.1371/journal.pone.0220605
    as

    Download full text from publisher

    File URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0220605
    Download Restriction: no
    File URL: https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0220605&type=printable
    Download Restriction: no
    File URL: https://libkey.io/10.1371/journal.pone.0220605?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    References listed on IDEAS

    as
    1. Bahr Weiss & Amie Alley Pollack, 2017. "Barriers to global health development: An international quantitative survey," PLOS ONE, Public Library of Science, vol. 12(10), pages 1-23, October.
    2. Marco Liverani & Benjamin Hawkins & Justin O Parkhurst, 2013. "Political and Institutional Influences on the Use of Evidence in Public Health Policy. A Systematic Review," PLOS ONE, Public Library of Science, vol. 8(10), pages 1-9, October.
    3. Morgan, Steve & Grootendorst, Paul & Lexchin, Joel & Cunningham, Colleen & Greyson, Devon, 2011. "The cost of drug development: A systematic review," Health Policy, Elsevier, vol. 100(1), pages 4-17, April.
    4. Todd Gammie & Christine Y Lu & Zaheer Ud-Din Babar, 2015. "Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries," PLOS ONE, Public Library of Science, vol. 10(10), pages 1-24, October.
    5. Vincent Ahonkhai & Samuel F Martins & Alexandre Portet & Murray Lumpkin & Dan Hartman, 2016. "Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization," PLOS ONE, Public Library of Science, vol. 11(11), pages 1-12, November.
    6. Mueller-Langer, Frank, 2013. "Neglected infectious diseases: Are push and pull incentive mechanisms suitable for promoting drug development research?," Health Economics, Policy and Law, Cambridge University Press, vol. 8(2), pages 185-208, April.
    7. Maryam Bigdeli & Shamsa Zafar & Hafeez Assad & Adbul Ghaffar, 2013. "Health System Barriers to Access and Use of Magnesium Sulfate for Women with Severe Pre-Eclampsia and Eclampsia in Pakistan: Evidence for Policy and Practice," PLOS ONE, Public Library of Science, vol. 8(3), pages 1-9, March.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Shiyong Wu & Wenxin Chen & Wei Chen & Wen Zheng, 2022. "Effects of Cultural Intelligence and Imposter Syndrome on School Belonging through Academic Resilience among University Students with Vocational Backgrounds," IJERPH, MDPI, vol. 19(13), pages 1-16, June.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Nicholas Bagley & Benjamin Berger & Amitabh Chandra & Craig Garthwaite & Ariel D. Stern, 2018. "The Orphan Drug Act at 35: Observations and an Outlook for the Twenty-First Century," NBER Chapters, in: Innovation Policy and the Economy, Volume 19, pages 97-137, National Bureau of Economic Research, Inc.
    2. Daniel Tobias Michaeli & Thomas Michaeli & Sebastian Albers & Tobias Boch & Julia Caroline Michaeli, 2024. "Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 25(6), pages 979-997, August.
    3. Jason C Hsu & Huai-Chueh Wu & Wen-Chia Feng & Chih-Ho Chou & Edward Chia-Cheng Lai & Christine Y Lu, 2018. "Disease and economic burden for rare diseases in Taiwan: A longitudinal study using Taiwan’s National Health Insurance Research Database," PLOS ONE, Public Library of Science, vol. 13(9), pages 1-14, September.
    4. Padmashree Gehl Sampath, 2022. "Strade Measures On Pharmaceutical Products: Can They Promote Local Production And Public Health?," Asia-Pacific Sustainable Development Journal, United Nations Economic and Social Commission for Asia and the Pacific (ESCAP), vol. 29(2), pages 47-69, November.
    5. Norah L. Crossnohere & Ryan Fischer & Andrew Lloyd & Lisa A. Prosser & John F. P. Bridges, 2021. "Assessing the Appropriateness of the EQ-5D for Duchenne Muscular Dystrophy: A Patient-Centered Study," Medical Decision Making, , vol. 41(2), pages 209-221, February.
    6. Pereira, Cristiano Gonçalves & Lavoie, Joao Ricardo & Garces, Edwin & Basso, Fernanda & Dabić, Marina & Porto, Geciane Silveira & Daim, Tugrul, 2019. "Forecasting of emerging therapeutic monoclonal antibodies patents based on a decision model," Technological Forecasting and Social Change, Elsevier, vol. 139(C), pages 185-199.
    7. Adrian Towse;Jimena Ferraro;Jorge Mestre-Ferrandiz, 2017. "Incentives for New Drugs to Tackle Anti-Microbial Resistance," Briefing 001842, Office of Health Economics.
    8. Cyr, Pascale Renée & Jain, Vageesh & Chalkidou, Kalipso & Ottersen, Trygve & Gopinathan, Unni, 2021. "Evaluations of public health interventions produced by health technology assessment agencies: A mapping review and analysis by type and evidence content," Health Policy, Elsevier, vol. 125(8), pages 1054-1064.
    9. Samira Guennif, 2022. "Capture and passive predation in times of COVID-19 pandemic," Public Choice, Springer, vol. 193(3), pages 163-186, December.
    10. Erik Landfeldt & Josefin Edström & Cecilia Jimenez-Moreno & Baziel G. M. Engelen & Janbernd Kirschner & Hanns Lochmüller, 2019. "Health-Related Quality of Life in Patients with Adult-Onset Myotonic Dystrophy Type 1: A Systematic Review," The Patient: Patient-Centered Outcomes Research, Springer;International Academy of Health Preference Research, vol. 12(4), pages 365-373, August.
    11. Weldon, Isaac & Parkhurst, Justin, 2022. "Governing evidence use in the nutrition policy process: evidence and lessons from the 2020 Canada food guide," LSE Research Online Documents on Economics 112430, London School of Economics and Political Science, LSE Library.
    12. Feng Xie, 2018. "Highly Priced Gene Therapies: A Wake-Up Call for Early Price Regulation," PharmacoEconomics, Springer, vol. 36(8), pages 883-888, August.
    13. Marijn A. Weele & Frank J. Rijnsoever & Menno Groen & Ellen H. M. Moors, 2020. "Gimme shelter? Heterogeneous preferences for tangible and intangible resources when choosing an incubator," The Journal of Technology Transfer, Springer, vol. 45(4), pages 984-1015, August.
    14. Vargas-Peláez, Claudia Marcela & Soares, Luciano & Rover, Marina Raijche Mattozo & Blatt, Carine Raquel & Mantel-Teeuwisse, Aukje & Rossi Buenaventura, Francisco Augusto & Restrepo, Luis Guillermo & L, 2017. "Towards a theoretical model on medicines as a health need," Social Science & Medicine, Elsevier, vol. 178(C), pages 167-174.
    15. Nilubon Subsittipong & Junjeong Choi & Tae Hyun Kim & Euna Han, 2022. "Delay in Vaccine Access in ASEAN Countries," IJERPH, MDPI, vol. 19(7), pages 1-13, March.
    16. Pejcic, Ana V. & Iskrov, Georgi & Jakovljevic, Mihajlo Michael & Stefanov, Rumen, 2018. "Access to orphan drugs – comparison across Balkan countries," Health Policy, Elsevier, vol. 122(6), pages 583-589.
    17. Uwe Kehrel & Kai Klischan & Nathalie Sick, 2016. "Why Research Partnerships Fail in the Biotechnology Sector — An Empirical Analysis of Strategic Partnerships," International Journal of Innovation and Technology Management (IJITM), World Scientific Publishing Co. Pte. Ltd., vol. 13(01), pages 1-23, February.
    18. Oliver, Edward & Kourouklis, Dimitrios & Jofre-Bonet, Mireia, 2024. "Do R&D tax credits impact pharmaceutical innovation? Evidence from a synthetic control approach," Research Policy, Elsevier, vol. 53(8).
    19. Charles Baum & Katherine Andino & Eric Wittbrodt & Shelley Stewart & Keith Szymanski & Robin Turpin, 2015. "The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA," PharmacoEconomics, Springer, vol. 33(7), pages 643-653, July.
    20. Se Hee Lee & Seung-Lai Yoo & Joon Seok Bang & Jong Hyuk Lee, 2020. "Patient Accessibility and Budget Impact of Orphan Drugs in South Korea: Long-Term and Real-World Data Analysis (2007–2019)," IJERPH, MDPI, vol. 17(9), pages 1-8, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:plo:pone00:0220605. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: plosone (email available below). General contact details of provider: https://journals.plos.org/plosone/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.